The Women’s Health Initiative: What Changed About HRT Since 2002

Medically reviewed by Meg LaFerriere, APRN · Ageless KC, Lee’s Summit, MO

If your mom or doctor told you hormone therapy causes cancer and heart attacks, that advice probably traces back to one study in 2002. Here’s what it found, and why experts see it differently today.

What was the Women’s Health Initiative?

The Women’s Health Initiative (WHI) was a large set of studies funded by the National Institutes of Health. Its hormone trials enrolled more than 27,000 postmenopausal women to see whether hormone therapy prevented heart disease and other chronic conditions.

There were two hormone arms:

• Estrogen plus progestin for women with a uterus, using conjugated equine estrogens and medroxyprogesterone acetate
• Estrogen alone for women who had had a hysterectomy

In 2002, the estrogen plus progestin arm was stopped early. Researchers found higher rates of breast cancer, heart attack, stroke and blood clots compared with placebo. The news was everywhere, and prescriptions for hormone therapy fell dramatically.

Who was in the study?

This detail changed everything. The average age of women in the WHI hormone trials was about 63. Many were more than 10 years past menopause, and most weren’t taking hormones for hot flashes.

That’s a very different group from a 51-year-old woman with night sweats who just stopped having periods. Starting hormones years after menopause, when blood vessels may already have plaque, appears to carry different risks than starting near menopause.

What is the timing hypothesis?

The timing hypothesis is the idea that when you start hormone therapy affects its risks and benefits. Later analyses of WHI data, along with other studies, found that women who began hormone therapy before age 60 or within 10 years of menopause had more favorable outcomes than those who started later.

Starting hormone therapy	General benefit-risk picture (healthy women)
Under 60 or within 10 years of menopause	Benefits generally outweigh risks for bothersome symptoms and bone loss prevention
60 or older, or more than 10 years past menopause	Higher absolute risks of heart disease, stroke, clots and dementia; needs careful individual review

This is the framework in The Menopause Society’s 2022 Hormone Therapy Position Statement. It doesn’t mean hormone therapy is risk-free for younger women. It means the balance usually tips toward benefit for healthy women with symptoms in that window.

What did the estrogen-alone arm show?

The estrogen-alone results got less attention. Women who had a hysterectomy and took estrogen alone did not show the increase in breast cancer seen in the combined arm. Long-term follow-up even found a lower rate of breast cancer in that group.

That doesn’t mean estrogen prevents breast cancer, and it doesn’t apply to women with a uterus, who need progesterone. It does show that “HRT causes breast cancer” is too simple a summary.

What does this mean for you today?

Hormone therapy decisions are now individual. Your age, time since menopause, symptoms, personal history and family history all matter, along with the type of hormones and how you take them.

Modern options also differ from what WHI tested. Transdermal estradiol and micronized progesterone weren’t part of the trial, and observational data suggest they may carry lower clot risk. Those options still need a careful review of your history.

If you’re in the Kansas City area and stopped hormones years ago out of fear, or never started, it’s reasonable to revisit the question. At Ageless KC, your practitioner reviews your history and labs and walks you through what the research means for your situation. Learn more about our women’s hormone program.

Frequently asked questions

Was the Women’s Health Initiative wrong?

No. It was a well-designed trial that answered an important question about older women starting hormones for disease prevention. The problem was applying its results to every woman, including younger women with symptoms.

Did the WHI study bioidentical hormones?

No. The trials used conjugated equine estrogens and medroxyprogesterone acetate. Estradiol and micronized progesterone, the most common bioidentical options, were not tested in the WHI.

Is hormone therapy recommended to prevent heart disease?

No. Current guidance does not recommend starting hormone therapy only to prevent heart disease or other chronic illness. It’s used to treat symptoms and to prevent bone loss in appropriate women.

Sources: Women’s Health Initiative (JAMA, 2002) and long-term follow-up; The Menopause Society 2022 Hormone Therapy Position Statement; NIH National Heart, Lung, and Blood Institute; Endocrine Society

This article is for general education and isn’t medical advice. Treatments aren’t right for everyone, and results vary. Our practitioner reviews your health history before any treatment.